1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ESC: Kerendia Hits In Heart Failure, But Usage Unclear

 
• By Elizabeth Cairns

Bayer’s mineralocorticoid receptor antagonist is effective in heart failure with mildly reduced or preserved ejection fraction – but should it be used instead of SGLT2s, or on top of them?    

Bayer US

Currently just one class of drugs is recommended for the treatment of patients with heart failure with mildly reduced or preserved ejection fraction: the SGLT2 inhibitors, namely Jardiance and Farxiga. Data presented at the annual congress of the European Society of Cardiology in London on 1 September could change that.

Key Takeaways
  • In the FINEARTS-HF trial, Bayer’s Kerendia reduced the risk of cardiovascular death and heart failure events by 16% over placebo.
  • This is slightly less effective than the...

Full data from the FINEARTS-HF trial of Bayer AG’s Kerendia (finerenone), toplined a hit last month, shows that the mineralocorticoid receptor antagonist reduced the risk of cardiovascular death and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.